UTHR catalysts
Catalysts and events linked to UTHR, newest first.
UTHR stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs 2026-09-14 · Mixed | prostacyclin franchise market share defense | Source notes direct competitive pressure and patent disputes between Liquidia and United Therapeutics. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues 2026-09-14 · Mixed | market share erosion in pulmonary arterial hypertension franchise | United Therapeutics is defending its market share through active patent litigation against Liquidia. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Lawsuit 2026-09-13 · Mixed | treprostinil market share defense against generic dry-powder competition | United Therapeutics defends market exclusivity via active patent enforcement. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle 2026-09-13 · Mixed | PAH market share defense and patent exclusivity enforcement | United Therapeutics is in active patent litigation defending treprostinil against Yutrepia. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit 2026-09-13 · Down | market share erosion in inhaled prostacyclin therapies | Competitor Yutrepia scaled to 5,000 patients in shared therapeutic category | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Continues 2026-09-12 · Mixed | PAH market share contestability and patent defense durability | Ongoing patent litigation with Liquidia over competing treprostinil formulations. | Not recorded |
| Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs 2026-09-12 · Watch | market share defense in pulmonary arterial hypertension inhalables | United Therapeutics in active patent litigation against Liquidia's Yutrepia formulation. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation Lingers 2026-09-12 · Mixed | competitive market share contestation in treprostinil therapies | Direct competitor named in active patent dispute with Liquidia over Yutrepia. | Not recorded |
Do these developments change your position?
Review UTHR alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-14Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation HangsLQDA UTHR
- 2026-09-14Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight ContinuesLQDA UTHR
- 2026-09-13Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics LawsuitLQDA UTHR
- 2026-09-13Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent BattleLQDA UTHR
- 2026-09-13Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent SuitLQDA UTHR
- 2026-09-12Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fightUTHR
- 2026-09-12Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fightUTHR
- 2026-09-12Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation loomsUTHR
- 2026-09-12Liquidia Logs 5,000 Yutrepia Patients Amid Ongoing Litigation with UTHRUTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle PersistsUTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle PersistsLQDA UTHR
- 2026-09-12Liquidia Logs 5,000 Yutrepia Patients Amid Ongoing Litigation with UTHRLQDA UTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Starts as United Therapeutics Patent Battle Weighs on StockLQDA UTHR
- 2026-09-12Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation loomsLQDA UTHR
- 2026-09-12Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation loomsLQDA UTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation ContinuesLQDA UTHR
- 2026-09-12Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighsLQDA UTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation LingersLQDA UTHR
- 2026-09-12Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fightLQDA UTHR
- 2026-09-12Liquidia reaches 5,000 Yutrepia patients amid United Therapeutics patent litigationLQDA UTHR
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.